Business
Preliminary clinical results for Entia Biosciences, Inc.’s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three months
Preliminary clinical results for Entia Biosciences, Inc.’s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three months.
About this update from Entia Biosciences Inc
[{"type":"text","content":"\n\n PORTLAND, Ore., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported better-than-expected preliminary results in the Company’s chronic kidney disease study being conducted on the island of Bonaire. Statistical analysis of the preliminary study results indicates, at a 95 percent confidence level, that three out of four consumers could reasonably expect a ten per cent increase in filtration rate. Dr. Hausman stated, “Our preliminary results exceeded our expectations and represent new hope for patients facing the challenge of stage 2,3, or 4 CKD.” The data, analyzed by an independent statistical analysis organization, reflect results for 22 study participants, all of whom suffer from stage 2, 3 or 4 CKD. Entia is also conducting an additional study that is underway in the South American nation of Colombia.\n According to the National Kidney Foundation, chronic kidney disease effects 26 million people in the U.S. The incidence of recognized CKD in people aged 65 and older has more than doubled between 2000 and 2008(1). The annual cost to treat CKD Medicare patients is $57.5 Billion, and represents 28% of the Medicare budget(2). Tragically, the disease represents over 85 thousand deaths in the U.S. each year and is the ninth leading cause of death.  Entia Biosciences says that it anticipates that adding its medical food supplement to existing standards of medical care for CKD will cost consumers only $2.00 per day. Hector Rodriguez, MD, PhD, a respected nephrologist who has served as a consultant to Entia, commented on these early results saying, “I have advised Entia Biosciences for several years during the development of the ErgoD2 medical food product. Early results from the recent Entia clinical study in stage 2, 3 and 4 CKD patients appears to confirm that promise. The potential for a significant improvement in the standard of care for chronic kidney disease is possible.”  Dr. Rodriguez is the Medical Director of a free-standing dialysis center located near the Cedars-Sinai Medical Center campus in Los Angeles. Michael Hermelijn, MD and Medical Director of the Bonaire Medical Clinic, Bonaire, BES, where the initial clinical results were obtained, has advised Entia that, “Prelimi...